



REQUEST FOR PROPOSAL

UNITED NATIONS CHILDREN'S FUND (UNICEF)
wishes to receive proposals for

Inactivated Poliovirus Vaccines

FOR DELIVERY DURING THE PERIOD 2028 – 2030

RFP-DAN-2026-503926

Date: 31 July 2026

PROPOSALS must be sent to the email supplybid@unicef.org up to
5.00 PM (Copenhagen time) Date: 4 September 2026.

Reference to RFP-DAN-2026-503926 should be made in the subject line of the email.
Proposals sent to a different email will be **INVALIDATED**, even if received before the
stipulated deadline.

**PROPOSALS RECEIVED IN ANY OTHER MANNER AND PROPOSALS RECEIVED
AFTER THE STIPULATED DATE AND TIME WILL BE INVALIDATED**

Prepared by: Mr Ian Lewis, Contracts Specialist

Approved by:

Ann Ottosen

Ms. Ann Ottosen
Senior Manager
Vaccine Centre
Supply Division, UNICEF

Katinka Rosenbom

Ms Katinka Rosenbom
Senior Contracts Manager
Quality Assurance and Policy Centre
Supply Division, UNICEF

TABLE OF CONTENTS

Section	Section Title	Page
TITLE PAGE	REQUEST FOR PROPOSAL DAN-2026-503926	1
PART I	PURPOSE OF THIS REQUEST FOR PROPOSAL	3
PART II	ELIGIBILITY AND PROPOSAL SUBMISSION PROCESS	11
PART III	COMMERCIAL REQUIREMENTS	19
PART IV	EVALUATION OF PROPOSALS; AWARDS	27
PART V	BIDDER REPRESENTATIONS	34
PART VI	ANSWER SHEETS	38

Annex	Annex Title
A.	UNICEF General Terms and Conditions of Contract (Goods)
B.	Mandatory Technical Requirements
C.	UNICEF Specifications for Vaccine Barcodes and data upload to Traceability and Verification system (TRVST)

PART I – PURPOSE OF THIS REQUEST FOR PROPOSAL

1. PURPOSE

1.1 UNICEF promotes the rights and wellbeing of every child in everything we do. Together with our partners, we work in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere. The fundamental mission of UNICEF is to promote the rights of every child, everywhere, in everything the organization does — in programs, in advocacy and in operations. The equity strategy, emphasizing the most disadvantaged and excluded children and families, translates this commitment to children's rights into action. For UNICEF, equity means that all children have an opportunity to survive, develop and reach their full potential, without discrimination, bias or favoritism. To the degree that any child has an unequal chance in life — in its social, political, economic, civic and cultural dimensions — her or his rights are violated. There is growing evidence that investing in the health, education and protection of a society's most disadvantaged citizens — addressing inequity — not only will give all children the opportunity to fulfil their potential but also will lead to sustained growth and stability of countries. This is why the focus on equity is so vital. It accelerates progress towards realizing the human rights of all children, which is the universal mandate of UNICEF, as outlined by the Convention on the Rights of the Child, while also supporting the equitable development of nations.

1.2 UNICEF vaccine procurement is guided by the principle of vaccine security: the sustained, uninterrupted supply of affordable vaccines of assured quality.

1.3 UNICEF is one of the largest procurers of supplies and services in the United Nations. These supplies and services have a wide-ranging impact on children, their environment, health, learning, protection and inclusion. Given the scale of UNICEF's vaccine procurement and the importance of 'leading by example', how UNICEF pursues procurement is important in its own right but also in relation to the Sustainable Development Goals (SDGs), particularly Goal 12 – "Ensure Sustainable Consumption and Production Patterns" and its target 12.7 – "promote public procurement practices that are sustainable, in accordance with national policies and priorities." UNICEF's vision is to become a leading practitioner and contributor to the UN sustainable procurement. Sustainable procurement, guided by the principle of environmental, social and economic sustainability, is critical to UNICEF's supply and logistics operations.

1.4 The purpose of this Request for Proposal (RFP) is to establish Long-Term Arrangement(s) for the supply of Inactivated Poliovirus Vaccines (IPV) through UNICEF for the period of January 2028 through December 2030 with an option to extend for up to two years.

The goal and procurement approach are in support of the accelerated switch to hexavalent vaccines with the programmatic and operational improvements this will have for countries as well as the opportunity for improved polio protection through increased coverage in several countries and earlier vaccination with IPV in a combination vaccine. This will also support the Global Polio Eradication Initiative (GPEI) strategy for bOPV removal currently planned for 2030 which require all countries to have at least 2 doses of IPV by 2028.

Securing continued access to affordable quality assured IPV for countries that decide not to transition to hexavalent vaccine, for example, due to their schedule having two doses of a fractional dose of IPV –

1/5th – instead of a full 0.5 ml two dose schedule (fractional dosing/fIPV), will be a critical deliverable as well.

2. BACKGROUND

2.1 Background and Current Market Analysis Section

a) **Product Description**

The vaccine requested under the tender is the **standalone IPV**, which is a suspension of types 1, 2 and 3 inactivated polioviruses. The product presentations required are 1, 5 and 10 dose vials, with a Vaccine Vial Monitor (VVM) affixed onto the individual vial.

UNICEF will request vaccine manufacturers to submit offers for all types of IPV, including Sabin IPV (sIPV), adjuvanted IPV or any other product that could become available during the tender period. For the longer term the programmatic preference may switch to products that support the GPEI strategy *Sustaining a Polio-free World*¹ (SPW) with technologies that do not rely on live polio viruses for vaccine production such as Virus Like Particles (VLP) which will reduce the risks of polio viruses being reintroduced unintentionally through the manufacturing process.

b) **Programme Background/Programmatic Update**

In 2025, the Polio Eradication Strategy 2022–2026: *Delivering on a promise* was extended to 2029. Based on the epidemiology at the time and after critical analysis and expert consultations, the Strategy Committee and Polio Oversight Board (POB) of the GPEI decided to extend the timeline for certifying the eradication of wild poliovirus type 1 (WPV1) to the end of 2027 and certifying the elimination of circulating type 2 variant poliovirus (cVDPV2), also known as vaccine derived poliovirus, to the end of 2029. During this strategy extension period, the GPEI will continue to build the foundation to sustain a polio-free world once it is achieved. Ensuring resilience through this transition will be critical to keep the world polio-free. The technical and financial requirements for essential functions that are needed to keep the world polio-free, including options for future governance and accountability, initially outlined in the *Polio Post-Certification Strategy* now updated in the SPW. This strategy was presented to the POB in March 2026 and has been adopted by Member States at the World Health Assembly, in May 2026.

The SPW strategy outlines what is required for a successful withdrawal of bOPV and one of the triggers endorsed by the Strategic Advisory Group of Experts (SAGE) to WHO in September 2024 was that all countries must have established i) at least two doses of IPV in their routine schedules, for ii) a minimum of two years prior to bOPV cessation, which is currently expected to occur in 2030. As of July 2026, there are 18 countries with only one dose of IPV in their immunization schedule, and of these 13 countries are eligible for support from Gavi, the Vaccine Alliance (Gavi).

In September 2024, SAGE reviewed its recommendation for IPV use in outbreak response, and while acknowledging that OPV is the primary tool for outbreak response it noted that in low and middle-income country settings where WPV1 or cVDPV outbreaks occur IPV can be administered concomitantly with nOPV2 (or bOPV if VDPV1 or 3 viruses circulate) in outbreak

¹ [sustaining-a-polio-free-world-executive-summary-eng-20260515.pdf](#)

response campaigns. The polio outbreak response *Standard Operating Procedure* has now been updated to include IPV as part of the outbreak response.

c) Procurement Goals and Specific Objectives

The goal and procurement approach are in support of the accelerated switch to hexavalent vaccines with the programmatic and operational improvements this will have for countries as well as the opportunity for improved polio protection through increased coverage in several countries and earlier vaccination with IPV in a combination vaccine. This will also support the Global Polio Eradication Initiative (GPEI) strategy for bOPV removal currently planned for 2030 which require all countries to have at least 2 doses of IPV by 2028

Securing continued access to affordable quality assured IPV for countries that decide not to transition to hexavalent vaccine, for example, due to fractional dosing, will be a critical deliverable as well.

Considering the current funding shortfall to implement Gavi's 5 years strategy for 2026-2030 - Gavi 6.0 - and the funding constraints of the GPEI, the specific objectives of this tender are:

- To ensure access to an affordable IPV for all countries that choose to continue to use IPV standalone vaccine and support the GPEI use of IPV for outbreak response.
- To contribute to fulfil UNICEF's commitment for localisation of manufacturing provided proposals are in line with the affordability objective.
- Ensure that the supplier base for the IPV standalone market has the manufacturers that best serve the countries that want to continue to use IPV standalone in their routine programmes in the long term (up to 10 years following bOPV withdrawal).
- Contribute to increased sustainability of the vaccine market


d) Market Analysis

The global annual demand for stand-alone full dose IPV was around 171 million doses in 2025 for routine requirements. The routine demand through UNICEF for 85 countries which routinely request vaccines through UNICEF is estimated to be around 105 million doses for 2026. This level of demand is projected to reduce over the next 3 to 4 years, as countries transition to the hexavalent vaccine, to around 40 million doses by 2030 under a scenario of accelerated hexavalent switch.

UNICEF as the major buyer of stand-alone IPV has a considerable role and responsibility in this market with regards to access and affordability. This responsibility requires a careful strategic approach to continue to work with the manufacturers with products prequalified by WHO and those with a product in development.

Over the tender period 2023 to 2027 the supply offered to UNICEF from manufacturers with a WHO prequalified product increased to the level that is 3 to 4 times the UNICEF demand, see graph 1.

Graph 1: IPV capacity offered to UNICEF compared to UNICEF demand



e) Innovation and Pipeline Considerations

UNICEF encourages vaccine manufacturers with an IPV product in development to submit a proposal in response to the tender. This will enhance the visibility on the pipeline products including terms and conditions, milestones, and timelines to achieve WHO prequalification. Taking into consideration the uncertainty related to the demand, the changing market conditions, and the tender objectives, UNICEF may need to introduce new suppliers over the tender period.

If the product offered by the Proposer is not WHO pre-qualified, the Proposal must include a detailed plan on the timeline to obtain WHO pre-qualification. The timeline should include information regarding the product and plans for manufacturing and licensing:

- Product Development: Status and plans, including source of bulk antigens to be used.
- Clinical Trials: Trials conducted so far and planned, with timelines.
- National Regulatory Registration: Status and plans for registration, including NRA that would be responsible for release of finished product and planned product presentations; and
- File submission to WHO: Status and plans.

If the Proposer's bid is deemed of interest to UNICEF, UNICEF will advise the Proposer of such and will request that UNICEF be kept informed about the progress of the submitted timeline.

f) Demand Forecast

The RFP will cover demand from January 2028 through to the end of December 2030 with an option to extend by up to 2 years. At this stage there are several factors that will impact the future demand for IPV, therefore, this tender includes two demand scenarios:

- Accelerated Hexavalent Vaccine Transition (programmatic optimization)
- Limited Hexavalent Vaccine Transition

The premiss for the accelerated transition to hexavalent vaccine vs the limited transition scenario is earlier and broader hexavalent transition incentivised by achieving favourable pricing (at or close to parity with a course of pentavalent and IPV at 2026 weighted average prices) and a strong country signal and readiness.

Despite the challenging financial environment, the Gavi Board confirmed in July 2025 its commitment to support the development of the hexavalent program in virtue of the programmatic value and the role of hexavalent vaccine to ensure improved IPV coverage in support of the global polio eradication goals.

The Gavi IPV, Pentavalent and Hexavalent Strategic Demand Scenarios (SDS) were updated in April 2026 to reflect the Alliance partners agreement to pursue the hexavalent acceleration. The SDS are based on demand forecasts from the initially 73 countries supported by Gavi and therefore include volumes from self-procuring countries and PAHO countries.

The two SDS are based on the following assumptions:

1. Accelerated Hexavalent Transition (programmatic optimization), where:
 - a. 41 countries introduce hexavalent vaccine by 2030,
 - b. 7 additional countries introduce hexavalent vaccine by 2035, and
 - c. Hexavalent vaccine price reaches a level “at or close to parity with a course of Pentavalent and IPV based on the 2026 WAPs”.
2. Limited Hexavalent Transition, where:
 - a. 25 countries introduce hexavalent vaccine by 2030,
 - b. 6 additional countries introduce hexavalent vaccine by 2035, and
 - c. Hexavalent vaccine price stays at 2026 price level.

Gavi published² the updated SDS on the Gavi website in April 2026.

Forecasted demand for IPV through UNICEF

The below tables show the two demand scenarios for the Gavi supported countries procuring through UNICEF for the period 2028 to 2035.

Table 1: Forecast for IPV demand for 2028 through to 2035 - Accelerated Hexavalent Transition

Accelerated Hexa Switch	2028	2029	2030	2031	2032	2033	2034	2035
1 dose	700,000	400,000	400,000	400,000	400,000	400,000	400,000	400,000
5 dose	41,000,000	27,000,000	20,000,000	20,000,000	18,000,000	16,000,000	15,000,000	15,000,000
10 dose	37,000,000	21,000,000	21,000,000	6,000,000	6,000,000	6,000,000	6,000,000	6,000,000
Total	78,700,000	48,400,000	41,400,000	26,400,000	24,400,000	22,400,000	21,400,000	21,400,000

Table 2: Forecast for IPV demand for 2028 through to 2035 - Limited Hexavalent Transition

Base Hexa Switch	2028	2029	2030	2031	2032	2033	2034	2035
1 dose	700,000	700,000	700,000	400,000	400,000	400,000	400,000	400,000
5 dose	58,000,000	54,000,000	51,000,000	51,000,000	48,000,000	47,000,000	47,000,000	45,000,000
10 dose	37,000,000	21,000,000	21,000,000	20,000,000	20,000,000	20,000,000	20,000,000	20,000,000
Total	95,700,000	75,700,000	72,700,000	71,400,000	68,400,000	67,400,000	67,400,000	65,400,000

² [Public version of the SDS](#)

The demand forecast under the accelerated hexavalent transition assumes that the price achieved in the new hexavalent vaccine tender makes the switch neutral in relation to cost for countries.

Should price parity not be achieved or should countries decide not to switch to the hexavalent vaccine as forecasted then the demand forecast for IPV will be more in line with Table 2 which reflects the limited hexavalent transition scenario.

The forecast assumes the countries that use fIPV will continue to do so and the Middle Income Country demand includes all the countries that UNICEF have regularly procured for since 2020. The forecast for 2028 and 2029 also includes 2 million doses for outbreak response on behalf of the GPEI, which will be conditional to funding availability.

Considering the uncertainty around the demand, awards may be based on a combination of the two scenarios.

g) Bidder's forecasts to UNICEF

It is important that the supply forecasts made by each Bidder to UNICEF and included in the Proposals are accurate and realistic. Ensuring the supply of vaccines to immunization programmes depends largely upon the actual quantities offered by the Bidders in their Proposals and the need stated at country level. Inaccurate and unrealistic forecasts jeopardize supply security and may have a negative impact on immunization programs.

UNICEF is encouraging Proposals from Bidders with products in development and acknowledges that supply forecasts for such products may need further iterations and/or confirmations later in time.

h) Tender Period

The tender period will cover 1st January 2028 to 31st December 2030 with an option to extend for up to an additional 24 months to 31st December 2032 if the Proposal helps to achieve the objectives of the RFP.

i) Minimum Quantity Guarantees and Firm Contracting

To achieve the objectives of the RFP, UNICEF is open to consider contracting terms that address Suppliers' risks by providing the opportunity to present a comprehensive Proposal through the RFP process in line with Part III – Commercial Requirements, article 6.9. Therefore, UNICEF may consider innovative approaches to contracting, such as volume-based commitments as part of Bidders' Proposals, provided they help achieve the objectives of this solicitation process.

Subject to funding availability, such a commitment would be conditional upon a reciprocal commitment from an awarded Supplier to a defined quantity over a defined time period. In addition, any such commitment would be conditional to the Supplier's acceptance of clearly defined performance terms. Alternative contracting terms may be presented by Bidders as part of the Proposal submitted in response to this RFP.

2.2 Procurement Reference Group

Considering the strategic nature of the procurement to be undertaken, an advisory group – Procurement Reference Group (PRG) comprised of independent and partner experts - is established and has provided advice with regards to the objectives and procurement strategy. The

PRG will be reconvened after UNICEF's evaluation of Proposals to provide advice on award approach and procurement allocations upon request. The PRG may continuously provide input and advice to UNICEF throughout the duration of the tender. UNICEF will share summary information related to the proposal(s) and recommended award(s) with the PRG under strict confidentiality.

3. LONG TERM ARRANGEMENT(S)

- 3.1 UNICEF wishes to enter into non-exclusive Long Term Arrangement(s) (LTA) for the procurement of the vaccines (Goods) described in Section 2 above, with the specifications outlined in the schedules contained in this RFP, as required from time to time during the term of the LTA. It will be a provision of the LTA that UNICEF will not be committed to purchase any minimum quantity of these vaccines, unless UNICEF specifically agrees to do so in the LTA. UNICEF will not be liable for any cost in the event that no purchases are made under any resulting LTA(s).
- 3.2 Purchases will be made against Purchase Orders to be issued by UNICEF in accordance with the terms and conditions of any resulting LTA(s). Actual quantities to be purchased will vary from Purchase Order to Purchase Order.
- 3.3 Any quantities outlined in this RFP, are an estimated forecast of the total requirement for the duration of the LTA or, if so specified, an estimated forecast for the annual requirement. Any estimates are provided in good faith and will not in any way be deemed to be a commitment on the part of UNICEF regarding any quantity for future purchases.

4. DURATION

- 4.1 The proposed LTA will be valid for an initial period from 1st January 2028 to the 31st of December 2030.
- 4.2 The duration of the LTA may be extended for an additional period of up to two years, at UNICEF sole discretion and subject to agreement with the awarded Supplier on the terms of such extension and/or if required to ensure the uninterrupted supply of vaccines to the relevant programme.

5. RFP DOCUMENTS

- 5.1 This RFP is comprised of the following:
 - This document
 - Annex-A UNICEF General Terms and Conditions of Contract (Goods)
 - Annex-B Mandatory Technical Requirements
 - Annex-C UNICEF Specifications for Vaccine Barcodes and data upload to Traceability and Verification system (TRVST)
 - Answer Sheets:
 - Commercial Proposal
 - Proposal Form
 - Proposer Information Sheet
 - Commercial Proposal Sheet (Qualitative & Quantitative)
 - Vaccine Registration Status Sheet

Technical Proposal

- Technical Proposal Sheet
- Packing Details Sheet

- 5.2 This RFP is not an offer capable of being accepted or as creating any contractual or other legal rights. Nothing in, or in connection with, this RFP will give rise to any liability on the part of UNICEF.

PART II – ELIGIBILITY AND PROPOSAL SUBMISSION PROCESS

1. ELIGIBILITY; BIDDER INFORMATION

- 1.1 **Bidder.** The term “Bidder” refers to those companies that submit a Proposal pursuant to this RFP and “Proposal” refers to all the documents provided by the Bidder in its response to this RFP. A Bidder will only be eligible for consideration if it complies with the representations set out in Part V of this RFP, including the representations on ethical standards and conflicts of interest.
- 1.2 **Registration as a UNICEF Supplier.** UNICEF is part of the United Nations Global Marketplace (UNGM). All Bidders must be registered as a UNICEF Supplier through the UNGM prior to submitting a Proposal in response to this RFP. This must be done via the UNGM website at <http://www.ungm.org>. UNICEF will not accept Proposals from Bidders that are not registered in this way. Bidders must include their UNGM registration number in the *Proposer Information Sheet*.

During the tendering process, Bidders may be requested to provide a complete electronic copy of their most recent audited full year’s financial statements, with comparative figures for the previous years. UNICEF evaluates financial viability, ethical and legal issues to identify and mitigate fiduciary risks.

For more information on registration as UNICEF Supplier, Bidders can consult UNICEF’s website: <https://www.unicef.org/supply/suppliers-and-service-providers>.

- 1.3 **Joint Venture, Consortium or Association.**
- (a) If the Bidder is a group of legal entities that will form or have formed a joint venture, consortium or association at the time of the submission of the Proposal, each such legal entity will confirm in their joint Proposal that:
 - (i) they have designated one party to act as a lead entity, duly vested with authority to legally bind the members of the joint venture jointly and severally, and this will be evidenced by a Joint Venture Agreement among the legal entities, which will be submitted along with the Proposal; and
 - (ii) if they are awarded the LTA, the designated lead entity, who will be acting for and on behalf of all the member entities comprising the joint venture, will enter into the LTA with UNICEF.
 - (b) After the Proposal has been submitted to UNICEF, the lead entity identified to represent the joint venture will not be altered without the prior written consent of UNICEF.
 - (c) If a joint venture’s Proposal is selected for award, UNICEF will award the LTA to the joint venture, in the name of its designated lead entity. The lead entity will sign the LTA for and on behalf of all other member entities.
- 1.4 The description of the organization of the joint venture, consortium or association must clearly define the expected role of each of the entities in the joint venture, consortium or association in delivering the requirements of this RFP, both in the Proposal and the joint venture, consortium

or association agreement. All entities that comprise the joint venture, consortium or association will be subject to the eligibility and qualification assessment by UNICEF.

- 1.5 Proposals from Government Organizations. The eligibility of Bidders that are wholly or partly owned by the Government may be subject to UNICEF's further evaluation and review of various factors such as being registered as an independent entity, the extent of Government ownership/share, receipt of subsidies, mandate, access to information in relation to this RFP, and other factors.

2. MULTIPLE PROPOSALS AND PROPOSALS FROM RELATED ORGANIZATIONS; JOINT VENTURES

Multiple Proposals not Permitted

- 2.1 Except for alternative Proposals submitted in accordance with Part II, Section 4.6, Bidders will not submit more than one Proposal as part of this solicitation process.
- 2.2 If the Bidder is a group of legal entities that will form or have formed a joint venture, consortium or association at the time of the submission of the Proposal then neither the lead entity nor the member entities of the joint venture may submit another Proposal, either in its own capacity or as a lead entity or a member entity for another joint venture submitting another Proposal.
- 2.3 UNICEF reserves the right to reject separate Proposals submitted by two or more Bidders if the Bidders are related organizations and are found to have any of the following:
- (a) they have at least one controlling partner, director or shareholder in common; or
 - (b) any one of them receive or have received any direct or indirect subsidy from the other(s); or
 - (c) they have a relationship with each other, that gives one or more Bidders access to confidential information about, or influence over, the other Proposal(s); or
 - (d) they are subcontractors to each other's Proposal, or a subcontractor to one Proposal also submits another Proposal under its name as lead Bidder; or
 - (e) an expert proposed to be in the team of one Bidder participates in more than one Proposal received for this solicitation process.

3. PROPOSAL SUBMISSION SCHEDULE

3.1 Acknowledgement of receipt of RFP.

Bidders are requested to inform UNICEF as soon as possible by email to Ian Lewis, Contracts Specialist referenced at the front page of the RFP, with copy to Alan McNulty, Procurement Assistant at ilewis@unicef.org and amcnulty@unicef.org that they have received this RFP.

IMPORTANT: PROPOSALS ARE NOT TO BE SENT TO THE INDIVIDUAL(S) STATED ABOVE – ANY PROPOSALS SENT TO THE ABOVE NAMED INDIVIDUAL(S) WILL BE DISQUALIFIED.

3.2 Questions from Bidders.

Bidders are required to submit any questions in respect of this RFP by email to Ian Lewis and Alan McNulty at ilewis@unicef.org and amcnulty@unicef.org. The deadline for receipt of any questions is seven (7) calendar days before the Proposal Submission Deadline.

IMPORTANT: PROPOSALS ARE NOT TO BE SENT TO THE INDIVIDUAL(S) STATED ABOVE – ANY PROPOSALS SENT TO THE ABOVE NAMED INDIVIDUAL(S) WILL BE DISQUALIFIED.

Bidders are required to submit questions in writing and to keep all questions as clear and concise as possible.

UNICEF will compile the questions received. UNICEF may, at its discretion, at once copy any anonymized question and its reply to all other invited Bidders and/or post these on the UNGM website and/or respond to the question at a bid conference. After any such bid conference, a Questions and Answers document will be prepared and posted on the UNGM website. Information provided orally will not be considered in any way as a change to the RFP.

3.3 Errors or Ambiguities in the RFP.

Each Bidder acknowledges that UNICEF, its directors, employees and agents make no representations or warranties (express or implied) as to the accuracy or completeness of this RFP or any other information provided to the Bidders. Bidders are expected to immediately notify UNICEF in writing of any ambiguities, errors, omissions, discrepancies, inconsistencies or other faults in any part of the RFP, providing full details. Bidders will not benefit from such ambiguities, errors, omissions, discrepancies, inconsistencies, or other faults.

3.4 Amendments to RFP.

At any time prior to the Submission Deadline, UNICEF may, for any reason, whether at its own initiative or in response to a clarification requested by a prospective Bidder, modify the RFP by amendment. For RFPs available publicly online, amendments will also be posted publicly online. Further, all prospective Bidders that have received the RFP directly from UNICEF will be notified in writing of all amendments to the RFP. In order to afford prospective Bidders reasonable time in which to take the amendment into account in preparing their Proposals, UNICEF may, at its sole discretion, extend the Submission Deadline.

3.5 Samples

Sample packaging materials are required for this solicitation process for technical review.

• **In electronic format:** Each Proposal must include, with regard to each vaccine offered in the Proposal, samples of each of the following in electronic format:

- High-quality photo of vaccine primary container including closure and label;
- Electronic copy of primary container label;
- High-quality photo of vaccine diluent/buffer primary container, if applicable;
- High-quality photo of vaccine dropper or any other device and material to be provided in the secondary packaging, if applicable;
- Electronic copy of vaccine insert(s).
- High-quality photo of inner box.

• **In physical format:** Each Proposal must include, with regard to each vaccine offered in the Proposal, three (3) samples of each of the following:

- Vaccine primary container including closure and label;
- Vaccine diluent/buffer primary container, if applicable;
- Vaccine dropper or any other device and material to be provided in the secondary packaging, if applicable;
- Vaccine inserts;
- Inner box, including pictures or designs of barcodes on secondary pack and higher pack levels, including human readable information (HRI) - see Annex C for specifications.

Samples must be sent to UNICEF at the following address:

UNICEF Supply Division
Oceanvej 10-12
DK – 2150 Copenhagen
Denmark
Attention: Ian Lewis, Vaccine Center

Please note that samples shall be sent at room temperature and please do not send the shipping box/tertiary packaging.

If the samples provided are different from those submitted to WHO for pre-qualification, the differences should be explained.

Samples should be marked with the RFP number (stated on the front page of this document) and mailed to the address above, arriving at UNICEF's address above no later than the deadline for submitting Proposals.

If at the time of submission of a Proposal the Bidder is not able to provide the samples as stated above, the Bidder should provide explanation and an indication of when the samples could be provided. For products in development, where packaging material has not yet been developed, Bidders are requested to provide soft copy of mock-up of the artwork for UNICEF's record as soon as available.

Failure to provide samples in accordance with the instructions requested under this Section 3.5 may result in invalidation of the Proposal.

3.6 Submission Deadline

The deadline for submission of Proposals is as indicated on the front page of this document.

Any Proposals received by UNICEF after the Submission Deadline will be rejected.

3.7 Proposal opening

Proposals received prior to the stated closing time and date will be kept unopened. The Officer of the Bid Section will open the Proposal when the specified time has arrived, and no Proposal received thereafter will be considered. UNICEF will accept no responsibility for the premature opening of a Proposal which is not properly addressed or identified. Due to the nature of this RFP, there will be no public opening of Proposals.

4. PROPOSAL AND ANSWERING SHEETS

- 4.1 Bidders are invited to develop a proposal (the “Proposal”) that is responsive to the requirements listed in this RFP and provides a comprehensive explanation of the offer being made. The Proposal must include a signed PROPOSAL FORM in original.

The ANSWERING SHEETS have been provided to assist in the organization of the Proposal into COMMERCIAL PROPOSAL and TECHNICAL PROPOSAL. No price information should be contained in the TECHNICAL PROPOSAL. Apart from the PROPOSAL FORM, UNICEF encourages the proposers to submit The ANSWERING SHEETS in MS Word format, if possible.

- 4.2 Bidders are expected to fully utilize the opportunity of an RFP to include all relevant information in the Proposal including procurement and contracting methodologies which allows the Bidder to best contribute to achieving the procurement objectives.
- 4.3 The Bidder must provide sufficient information in the Proposal to address each area of evaluation to ensure that a fair assessment of the Proposal can be conducted.
- 4.4 Only the forms and answering sheets provided in Part VI should be used to present the various aspects of the Commercial and Technical Proposal. Supplementary information can be provided on each of the answering sheets:

COMMERCIAL PROPOSAL:

- PROPOSAL FORM
- PROPOSER INFORMATION SHEET
- COMMERCIAL PROPOSAL SHEET (QUANTITATIVE AND QUALITATIVE)
- VACCINE REGISTRATION STATUS SHEET

TECHNICAL PROPOSAL:

- TECHNICAL PROPOSAL SHEET
- PACKING DETAIL SHEET

- 4.5 The Proposal should, at a minimum:
- Include the statement of acceptance of the RFP and resulting LTA terms and conditions and certify the date of validity of the Proposal (PROPOSAL FORM).
 - Contain all the requested information confirming Bidder’s eligibility in PROPOSER INFORMATION SHEET.
 - Define the commercial Proposal through both, qualitative information on Bidder’s past performance and organizational structure as well as information on price and quantities in the COMMERCIAL PROPOSAL SHEET which consists of QUALITATIVE and QUANTITATIVE Proposals.
 - Contain information required for technical evaluation of proposals, including TECHNICAL PROPOSAL SHEET and PACKING DETAILS SHEET.

- The COMMERCIAL and TECHNICAL Proposals can be submitted in one e-mail, it is NOT a requirement to submit COMMERCIAL and TECHNICAL Proposals through separate e-mails.

4.6 Bidders are invited to offer alternative products and presentations in response to this RFP. COMMERCIAL PROPOSAL SHEET includes an option for ALTERNATIVE PROPOSAL for Bidders who wish to offer alternative vaccine presentation(s). It can be submitted in several copies if multiple alternatives will be offered.

5. LANGUAGE

5.1 The Proposal prepared by the Bidder and all correspondence and documents relating to the Proposal exchanged by the Bidder and UNICEF, will be written in English. Supporting documents and printed literature provided by the Bidder should also be provided in English.

6. VALIDITY OF PROPOSALS; MODIFICATION AND CLARIFICATIONS; WITHDRAWAL

- 6.1 Validity Period. Bidders must indicate the validity period of their Proposal. Proposals should be valid for a period until 31 December 2030. A Proposal valid for a shorter period of time may not be further considered. UNICEF may request the Bidder to extend the validity period. The Proposal of Bidders who decline to extend the validity of their Proposal will become disqualified as no longer valid.
- 6.2 Corrections and Other Changes to the Proposal. All corrections or other changes to a Proposal must be received by UNICEF prior to the Submission Deadline. The Bidder must clearly indicate that the revised Proposal is a modification and supersedes the earlier version of their Proposal and clearly state and explain the changes from the original Proposal.
- 6.3 Withdrawal of Proposal. A Proposal may be withdrawn by the Bidder on emailed, faxed or written request received by UNICEF's Bid Section from the Bidder prior to Submission Deadline. Negligence on the part of the Bidder confers no right for the withdrawal of the Proposal after it has been opened.

7. PREPARATION OF PROPOSAL

- 7.1 It is the responsibility of Bidders to inform themselves in preparing their Proposal. In this regard, the Bidders must:
- Examine all terms, requirements and formal submission instructions (e.g. regarding form and timing of submission, marking of envelopes, as applicable) included in the RFP (including the Instruction to Bidders section);
 - Review the RFP to ensure that they have a complete copy of all documents;
 - Examine all of the Mandatory Technical Requirements and Other Mandatory Requirements;
 - Review the UNICEF General Terms and Conditions of Contract (Goods) for the supply of Goods attached to this RFP (and also publicly available on the UNICEF Supply website: <https://www.unicef.org/supply/documents/general-terms-and-conditions-contract>);
 - Review the UNICEF policies publicly available on the UNICEF Supply website: <https://www.unicef.org/supply/resources/procurement-policies>. In particular, Bidders should familiarize themselves with the obligations imposed on Suppliers and their personnel

and sub-contractors under the UNICEF Policy Prohibiting and Combatting Fraud and Corruption and the UNICEF Policy on Conduct Promoting the Protection and Safeguarding of Children;

- Fully inform and satisfy themselves as to requirements of any relevant authorities and laws that apply, or may in the future apply, to the supply of the Goods.

7.2 Failure to meet all requirements and instructions in the RFP or to provide all requested information will be at the Bidder's own risk and may result in rejection of the Bidder's Proposal.

7.3 The Proposal must be organized to follow the format of this RFP. Each Bidder must respond to the stated requests or requirements and indicate that the Bidder understands and confirms acceptance of UNICEF's stated requirements. The Bidder should identify any substantive assumption made in preparing its Proposal. The deferral of a response to a question or issue to any contract negotiation stage (if any) is not acceptable. Any item not specifically addressed in the Proposal will be deemed as accepted by the Bidder. Incomplete or inadequate responses, lack of response or misrepresentation in responding to any questions will affect the evaluation of the Proposal.

7.4 Submission of Proposals

Bidders must make clear reference to the RFP NUMBER in the subject field of email submitted to supplybid@unicef.org. Email submission shall not exceed 25 MB, including the size of the cover email. If the Proposal consists of large electronic files, it is recommended to send these files separately before CLOSING TIME AND DATE, indicating the order of emails (email 1, email 2, etc.) after the RFP NUMBER in the subject line of each email.

Bidders are expected to ensure the "acknowledge receipt" of the Proposal is received after the email submission. The subject line of an "acknowledge receipt" will show "UNICEF Supply Division - Bid confirmation".

No other recipient should be "cc" or "bcc" in the email submission.

Proposals sent to any other email, or without RFP NUMBER included in the subject field of email or Proposals sent after the CLOSING TIME AND DATE will be INVALIDATED.

7.5 Answer sheets must be completed in full by the Bidder.

7.6 Each Bidder acknowledges that its participation in any stage of the solicitation process for this RFP is at its own risk and cost. The Bidder is responsible for, and UNICEF is not responsible for, the costs of preparing its Proposal or response to this RFP, submission of any samples, attendance at any bid conference, site visit, meetings or oral presentations, regardless of the conduct or outcome of the solicitation process.

8. PROPOSAL DOCUMENTS; CONFIDENTIALITY

8.1 This RFP, together with all Proposal documents provided by the Bidder to UNICEF, will be considered the property of UNICEF and will not be returned to the Bidders.

8.2 Information contained in the Proposal documents, or otherwise provided by the Bidder in connection with the Proposal, will be treated as confidential unless otherwise noted by the Bidder,

except that:

- UNICEF may share such information on a confidential basis with members of the Procurement Reference Group/Advisory Group as described in Part I, Section 2.
- UNICEF will make details of each award public as described in Part IV, Section 2.9.
- UNICEF reserves the right to disclose specific information regarding the Proposals with the Gavi in case of special contracting and funding provisions.

PART III – COMMERCIAL REQUIREMENTS

This section provides background information for completion of the Commercial Proposal. It also provides information on UNICEF's commercial requirements for awarded Suppliers under an eventual LTA and Purchase Order.

1. EXPERIENCE AND PAST PERFORMANCE; PROPOSED QUANTITIES

1.1 Experience in Vaccines and/or Biologicals Supply and Delivery. The Bidder will demonstrate proven experience and qualification in development, supply and delivery of the vaccines and/or biologicals including the offered product(s). The Bidder should provide the following information:

- Number of years of production and delivery by vaccine and/or biologicals (quantities).
- Applicable to all Bidders with less than 3 years of experience as a vaccine Supplier to UNICEF: Customer reference list by vaccine and/or biological. This should include customer contact names and communication information (phone/email/fax). Delivery report and delivery performance report for minimum period of the past 3 years, including reasons for delays in deliveries and frequency, and measures taken to resolve the delays. Information on total annual quantities supplied to other customers.
- Names of regulatory bodies where products are registered, and date of original registration.

The Bidder may also supply other information as it considers appropriate in order to demonstrate proven experience and qualification in the supply and delivery of the vaccines being proposed.

Bidders should be prepared to substantiate the claimed experience by presenting copies of relevant documents and references if so requested by UNICEF.

1.2 Past Performance Record. Bidders that have not previously supplied to UNICEF must demonstrate that they have been able to provide on-time deliveries and maintained production schedules; they must also specify the time period over which the on-time delivery performance has been measured. UNICEF will also review past performance of former and current Suppliers to UNICEF by reference to criteria set out in Part IV, Section 1.2.

1.3 Past Performance Record of Joint Ventures. Where a joint venture is presenting its track record and experience in a similar undertaking as those required in this RFP, it should present such information in the following manner:

- (a) Those that were undertaken together by the joint venture; and
- (b) Those that were undertaken by the individual entities of the joint venture expected to be involved in the performance of the activities defined in this RFP.

2. PRODUCT DETAILS, QUANTITIES AND PLANS

2.1 Reasonable Proposed Quantity. If the proposed quantity is disproportionally high compared to past years' annual production quantity, the Bidder will demonstrate, that it is able to supply the quantity being proposed by it to UNICEF during the quoted timeframe. The Bidder will also advise UNICEF of the current annual production quantity. WHO's Prequalification Team –

WHO/PQT - may evaluate the capacity of the Bidder to supply the proposed quantity as part of the technical evaluation of the Proposal.

- 2.2 Medium and Long Term Plans. Bidders are requested to provide information on their medium and long term plans for production of the vaccine(s) being offered, or of vaccines that may be offered in the future, including an overview of business factors affecting the decision to produce the vaccine at the quantities offered to UNICEF.
- 2.3 National Regulatory Licensure Requirements by the Importing Governments. Bidders are expected to undertake all reasonable efforts to ensure products are registered in the countries that require registration prior to use and to keep UNICEF informed of the progress and development of same. In addition to the information on existing registrations required under Section 1.1, Bidders are requested to provide information on planned and pending registrations and intent to renew existing registrations upon expiry.
- 2.4 Country of Origin. Bidders shall advise of country of origin of vaccines offered, including that for vaccines produced in countries other than that of the Bidder must be indicated, stating the country of origin. Bidders may be required to submit a Certificate of Origin of Goods issued by the Chamber of Commerce or other equivalent authority. *(Information shall be provided as part of Technical Proposal Sheet).*
- 2.5 Sub-contractors. Bidders must identify in their Proposal any products which may be offered by themselves but originate from another Supplier and/or country. All sub-contracting arrangements will be reviewed by UNICEF as part of its evaluation of the Proposal. In addition, all Bidders not producing the vaccine offered or their own vaccine bulk concentrate must indicate the source(s) for the vaccine quantity offered. Bidders will provide evidence of the contractual agreements for the quantities being offered. Furthermore, the Bidder must confirm that the quantities offered do not violate any contractual commitments made between the Bidder and the vaccine or bulk concentrate manufacturer. *(Information shall be provided as part of Technical Proposal Sheet).*
- 2.6 Catalogues. Bidders, who have not already done so, are kindly requested to include a copy of their current catalogue or list of products offering in their Proposal.

3. ACCOUNT MANAGEMENT

- 3.1 The Bidder will provide UNICEF with the names and reporting lines of the accountable lead focal points for each of the following key functions: Production, Quality Assurance, Governmental Affairs, Shipping/Logistics, Sales and Marketing, Environmental, Social and Governance (ESG), and Barcoding/Serialization. The Bidder must clearly specify the name of the primary contact person responsible for this proposal and the resulting contract.
- 3.2 UNICEF expects the primary contact person(s) to be able to execute the appropriate account management which includes accurate and reliable planning and forecasting, efficient order processing, accurate and complete documentation, close production follow up, facilitate timely submission to NRA for release and follow-up of the same, shipping and logistics, as well as any other related issues including fast response time to inquiries.

Communication and documentation shall be in English. The communication is seen as an

important prerequisite for successful account management and needs to be frequent, timely and accurate.

- 3.3 The communication on all elements connected to execution of an eventual LTA and subsequent Purchase Orders should be solely between UNICEF and the awarded Supplier. Suppliers are not expected to have direct contact with recipient country Governments.
- 3.4 Environmental – Social – Economic (ESE) Sustainability Reporting: All Suppliers awarded LTAs with UNICEF will be required to provide one annual report each year on ESE, at a time to be agreed, using UNICEF’s reporting format, which will be provided to the Supplier.
- 3.5 Traceability and Verification System (TRVST): UNICEF requests all Suppliers to preferably make product master, batch and serialization data of vaccines available via a digital interface to TRVST to enable (future) use of barcode scanning by countries. Suppliers are required to report on their plans to establish an interface to TRVST, where such an interface is not already in place.

4. PERFORMANCE MONITORING

As part of UNICEF’s continuous strive to improve the ability to provide products of the appropriate standards to UNICEF programs and partners and in a timely manner, monitoring of Suppliers’ performance will continue to be strengthened.

- 4.1 The UNICEF General Terms and Conditions of Contract (Goods) specify that UNICEF will monitor the Supplier’s performance under the LTA and linked Purchase Orders. As part of execution of an eventual LTA, the awarded Supplier will be required to provide its full cooperation with such performance monitoring, at no additional cost or expense to UNICEF, and provide relevant information as reasonably requested by UNICEF.
- 4.2 UNICEF has identified generic criteria that will be applied for evaluating and monitoring Supplier performance against their contractual obligations as an outcome of this procurement process.

Key Categories	Performance Metrics	Performance Baseline
Time	Timeliness of Purchase Order Acknowledgement	Less than or equal to 5 working days after Purchase Order placement
	Timeliness of Notification of Goods Readiness	Notification of Goods’ Readiness parameter (Greater than or equal to two weeks before the confirmed date of Readiness of Goods.)
	Timeliness of Delivery	Less than or equal to 5 working days after Purchase Order delivery date

5. MONTHLY ALLOCATION REPORTING

- 5.1 Under the LTA, the awarded Supplier will be required to provide UNICEF on or before the 30th of June with their initial monthly availability for the following year, which is expected to be

updated monthly.

6. PRICES AND DISCOUNTS

- 6.1 Bidders wishing to apply for funding from the Gavi-funded African Vaccine Manufacturing Accelerator ('AVMA') instrument in connection with this RFP must:
- Have obtained an in-principle eligibility statement from Gavi in respect of the Qualifying Vaccine to which this RFP relates prior to submission of the Proposal; and
 - Indicate in the Answer Sheets, Commercial Proposal Sheet, section A, Quantitative Proposal, the price offer prior to deducting any subsidy that may be applicable for the per dose accelerator payment.

Bidders are required to provide relevant information in the Answer Sheets, Commercial Proposal Sheet, section B. Qualitative Proposal, under Pricing.

- 6.2 Tiered Pricing. In accordance with its Vaccine Procurement Principles, UNICEF gives Bidders the option to quote tiered pricing based on the World Bank classification of countries by income level for countries not supported by Gavi.

- 6.3 Pricing based on Delivery Term. Bidders are requested to provide unit pricing in accordance with the following delivery terms (INCOTERMS 2020):

FCA – FCA named airport [SPECIFY NAME OF AIRPORT]

Failure to quote in accordance with the requested INCOTERMS may, in UNICEF's discretion, result in invalidation of the Proposal.

- 6.4 Currency of Proposals. The currency of the Proposal will be either 1) US Dollars or 2) US Dollars and EURO. Bidders wishing to offer in EURO are requested to offer one price in US Dollars and one price in EURO, leaving it to UNICEF's sole discretion to determine which price to accept and consider for award. For evaluation purposes, the EURO price will be converted to US Dollars using the official United Nations rate of exchange in effect on the submission deadline date.
- 6.5 Inclusive Pricing. Pricing should include the cost of packaging and packing the Goods and all temperature monitoring devices in accordance with the packaging and packing requirements set out in the Mandatory Technical Requirements. Bidders are requested to specify the price implications of temperature monitoring devices in the *Packing Details Answering Sheet*. Unit pricing must include the price of Vaccine Vial Monitor (VVM).
- 6.6 Taxes. Article II, Section 7, of the Convention on the Privileges and Immunities provides, inter alia, that the United Nations, including UNICEF as a subsidiary organ, is exempt from all direct taxes, except charges for public utility services, and is exempt from customs restrictions, duties, and charges of a similar nature in respect of articles imported or exported for its official use. All prices quoted in the Proposal must be net of any direct taxes and any other taxes and duties, unless otherwise specified in this RFP.
- 6.7 Affordability of Pricing. UNICEF believes in paying a price that is affordable to Governments and donors and a price that reasonably covers manufacturers' minimum requirements. The Bidder is requested to provide information on factors that influence the pricing offered to

UNICEF including, the basis for any quantity-based pricing. Any price increase over previous years' pricing should be explained in the *Commercial Proposal*.

- 6.8 Maximum Pricing. Prices offered by Bidders, will constitute maximum ceiling prices and cannot be increased for the duration of the tender period and during the validity of Proposal. Prices may be reduced at any time.
- 6.9 Most Favoured Customer. The Bidder confirms that the prices with respect to the Goods specified in the Proposal are the most favourable prices available to any customer of the Bidder (or any of the Bidder's affiliates). If the Bidder offers to sell the same Goods at a price lower than the price effective under the LTA, the Bidder will offer the same price to UNICEF for the remaining validity period of the LTA.
- 6.10 Discounts. Bidders are requested to advise as to:
- (a) Quantity / volume discounts, in form of large quantity / volume discounts and staircase pricing (i.e. varying prices according to different quantities procured);
 - (b) Cumulative quantity / volume discount levels, i.e. discounts that increase as the cumulative order value/volume increases throughout the validity of the LTA;
 - (c) Early payment discounts, i.e. payment within a specified period of time faster than UNICEF's standard payment term of 30 days net;
 - (d) Trade discounts;
 - (e) Any other unconditional discounts.

Any discount offered in the successful Proposal will be reflected in the awarded LTA and will be applied in the affected Purchase Orders issued under such LTA.

- 6.11 Alternative Proposals. UNICEF welcomes alternative Proposals, including Proposals which may include special contracting terms or where pricing is conditional upon firm UNICEF commitment to defined quantities, or subject to pre-payment or advance payments. Such Proposals will be evaluated against their utility in reaching the specific objective(s) of the RFP. Any firm commitment by UNICEF would be subject to funding availability as well as other agreed upon conditions, including reciprocity clauses (e.g. liquidated damages).
- 6.12 Payment Terms. Unless an alternative Proposal has been awarded that includes pre-payment or advance payment, invoices may be issued to UNICEF only after the delivery terms of the Purchase Order (as issued in accordance with the provisions of the LTA) have been fulfilled. The standard terms of payment are net 30 days, after receipt of invoice and required supporting documentation. Payment will be effected by bank transfer in the currency of the Purchase Order.

7 DELIVERY TERMS AND DELIVERY LEAD TIME; LIQUIDATED DAMAGES

- 7.1 Under the LTA, the awarded Supplier will be required to comply with the applicable INCOTERM and all other delivery terms and instructions stated in the LTA and the relevant Purchase Order. With respect to the definition of "INCOTERMS" in the UNICEF General Terms and Conditions of Contract (Goods), the applicable version of the "INCOTERMS" will be the most-recently issued version of the INCOTERMS at the start date of the LTA; provided however that if a new version of the INCOTERMS is issued after the effective date of the LTA, the Parties will in good faith consult with each other on the implications for the LTA with a view

to adopting such new version.

- 7.2 The awarded Supplier will be expected to comply with the delivery lead-time specified in the LTA. Bidders should therefore indicate the realistic lead-time for delivery for each vaccine offered (subject to quantities). “Delivery lead-time” is the period from the date of receipt of a Purchase Order by the Supplier to the date of delivery of the Goods in accordance with the applicable delivery term and instructions specified in the relevant Purchase Order (as issued in accordance with the provisions of the LTA) and includes the period for packing the products, delivery in accordance with the specified delivery term and provision of all documentation required in connection with such delivery. UNICEF will monitor and measure the performance of the Supplier, including by measuring performance against the lead-time indicated in its Proposal and reflected in the LTA. The maximum lead time should not exceed 30 calendar days. UNICEF may request IPV to be delivered as part of an outbreak response, in which case we would request the vaccine to be made ready with a shorter lead time than agreed in the LTA.
- 7.3 The Supplier’s obligations in respect of delay in delivery of Goods, including (but not limited to) obligations to notify UNICEF of delay in delivery of Goods, as well as the consequences of delay, and UNICEF’s rights and remedies in respect of any such delay, are governed by the UNICEF General Terms and Conditions of Contract (Goods).
- 7.4 The LTA also specifies that, without prejudice to any of the other rights and remedies of UNICEF, if the Supplier fails to deliver the Goods under any Purchase Order in accordance with the stated time for delivery, or if UNICEF exercises its right to reject Goods that do not conform to the requirements in the LTA and the relevant Purchase Order, UNICEF may claim liquidated damages from the Supplier and, at UNICEF’s option, the Supplier will pay such liquidated damages to UNICEF or UNICEF will deduct such liquidated damages from the Supplier’s invoice(s). Such liquidated damages will be calculated as follows: one half of one per cent (0.5%) of the price of such Goods for each day of delay, until delivery of conforming Goods, up to a maximum of ten per cent (10%) of the value of the relevant Purchase Order. The payment or deduction of such liquidated damages will not relieve the Supplier from any of its other obligations or liabilities pursuant to the LTA and the relevant Purchase Order.

8. PRE-DELIVERY INSPECTION

- 8.1 In the exceptional situation where the requirements of a country of destination specify pre-delivery inspection, then UNICEF may stipulate in a Purchase Order that the Goods to be supplied under that Purchase Order (as the case may be), are subject to pre-delivery inspection and the following provisions will apply:
- (a) Pre-delivery inspection will be conducted by an independent inspection agency selected by UNICEF or the relevant Consignee. The Supplier will not be responsible for the costs of such pre-delivery inspection.
 - (b) At UNICEF’s request, the Supplier will provide its reasonable cooperation to UNICEF and its designated inspection agency, at no additional cost to UNICEF.
 - (c) The Supplier will advise UNICEF of the location of the manufacturing facility/facilities. UNICEF will advise the Supplier of the name of the designated inspection agency.
 - (d) Notice of the readiness of each consignment of Goods, in the form attached to the Purchase Order, must be provided by the Supplier to UNICEF and the designated

inspection agency as soon as possible and at least **two weeks** prior to the Goods readiness date.

- (e) UNICEF will notify the Supplier promptly of its decision whether or not to release the Goods for shipment. If UNICEF issues a release notice, the Supplier will immediately expedite shipment of the released consignment. If UNICEF notifies the Supplier that the Goods are non-conforming, then Article 2.6 of the UNICEF General Terms and Conditions of Contract (Goods) will apply.

8.2 The awarded Supplier acknowledges that any inspection of the Goods by UNICEF or its designated inspection agents does not constitute a determination whether the specifications for the Goods (including Mandatory Technical Requirements) as set out in eventual LTA or any Purchase Order have been met. The awarded Supplier will be required to comply with its warranty and other contractual obligations whether or not UNICEF carries out such pre-delivery inspection of the Goods.

8.3 The pre-delivery inspection of the Goods undertaken by UNICEF or its designated inspection agents will not substitute for the inspection of the Goods upon delivery.

9. TEMPORARY STORAGE

9.1 Under an eventual LTA, the awarded Supplier will be required to properly store, from time to time and at no cost to UNICEF, finished products of vaccines for delivery at a later date. Storage of vaccines will be under controlled environmental conditions to facilitate the conservation of the vaccines. The storage facilities will comply with all national regulations for the storage of vaccines in force in the country where the storage facility is located.

10. WARRANTY

10.1 Warranty. Under an eventual LTA, the awarded Supplier will be required to warrant that the Goods (including packaging) offered by it will meet each of the following minimum criteria:

- (a) The Goods conform to the quality, quantity and specifications for the Goods stated in the LTA and linked Purchase Order (including, in the case of perishable or pharmaceutical products, the shelf life specified in the LTA and linked Purchase Order);
- (b) The Goods conform in all respects to the technical documentation provided by the Supplier in respect of such Goods and, if samples were provided to UNICEF prior to entering into the LTA, the Goods are equal and comparable in all respects to such samples;
- (c) The Goods are new and factory-packed;
- (d) The Goods are fit for the purposes for which such Goods are ordinarily used and any purposes expressly made known to the Supplier by UNICEF;
- (e) The Goods are free from defects in design, manufacture, workmanship and materials;
- (f) The Goods are free from all liens, encumbrances or other third party claims;
- (g) The Goods are contained or packaged in accordance with the standards of export packaging for the type and quantities of the Goods specified in the LTA and linked Purchase Order, and for the modes of transport of the Goods specified in the LTA and linked Purchase Order (including but not limited to, in a manner adequate to protect them in such modes of transport), and marked in a proper manner in accordance with the instructions stipulated in the LTA and linked Purchase Order and applicable law.

- 10.2 Warranty Period. Under the LTA, the period of validity of the warranty will be no less than the shelf life of the Goods.
- 10.3 Assignment of Manufacturer Warranties. If the Supplier is not the original manufacturer of the Goods or any part of the Goods, under the LTA, the Supplier will be expected to assign to UNICEF (or, at UNICEF's instructions, the Government or other entity that receives the Goods) all manufacturers' warranties in addition to any other warranties specified in the LTA and linked Purchase Order.
- 10.4 Extension of Warranty to Partners. The Bidder should note that, under the LTA, the warranties are expected to be made to UNICEF and to extend to (a) each entity that makes a direct financial contribution to UNICEF for the purchase of Goods; and (b) each Government or other entity that receives the Goods.

PART IV – EVALUATION OF PROPOSALS; AWARDS

1. EVALUATION

- 1.1 Evaluation. The evaluation is carried out by UNICEF in accordance with UNICEF's regulations, rules and practices and all determinations are made in UNICEF's sole discretion.

After opening the Proposals, the Proposals will be evaluated as follows:

- General. The merits of each Proposal will be evaluated to assess its ability to support the objectives of this RFP as set out in Part I. UNICEF will evaluate each Proposal to determine whether the products offered are acceptable commercially and technically and are of the required quality.
- Review of Compliance with Eligibility, Commercial and Technical Mandatory Requirements. Each Proposal will be evaluated for compliance with the requirements of this RFP.
- Technical evaluation will be based on information provided by Bidders as part of their Technical Proposal and evaluation will take place in accordance with the Mandatory Technical Requirements assessed in collaboration with WHO. Compliance with all other requirements will be evaluated by UNICEF.
- Proposals deemed not to meet all of the requirements will be considered non-compliant and rejected at this stage without further consideration. Failure to comply with any of the terms and conditions contained in this RFP, including, but not limited to, failure to provide all required information, may result in a Proposal being disqualified from further consideration.
- If the Proposal is deemed interesting in its potential ability to support the objectives of this tender and meets the Mandatory Technical Requirements, except that the product is not WHO pre-qualified, UNICEF will proceed as outlined in Section below.
- Commercial evaluation. During the evaluation, the nature of the Commercial Proposal will be studied and compared to the evaluation criteria. In order to determine to what extent a Proposal is found satisfactory, all information included in both the Commercial and Technical Proposal will be evaluated together to determine how the factors presented in each Proposal will support the RFP objectives set out in Part I.
- Products not yet WHO pre-qualified. If the product offered is not WHO pre-qualified, the Proposal must include a detailed plan on the timeline to obtain WHO pre-qualification. The timeline should include information regarding the product and plans for manufacturing and licensing:
 - ✓ Product Development: Status and plans, including source of drug substance to be used;
 - ✓ Clinical Trials: Trials conducted so far and planned, with timelines;

- ✓ National Regulatory Registration: Status and plans for registration, including NRA that would be responsible for release of finished product and planned product presentations; and
- ✓ File submission to WHO: Status and plans.

If the Bidder's Proposal was deemed of interest to UNICEF, UNICEF will advise the Bidder of such and will request that UNICEF be kept informed about the progress of the submitted timeline. If the proposed vaccine obtains WHO pre-qualification during the award period and upon confirmation that the mandatory requirements of the RFP are met, UNICEF would consider awarding a quantity to the Bidder under one or more of the following conditions:

- ✓ UNICEF is facing a monopoly situation or a near monopoly situation;
- ✓ Lack of performance of current supplier(s);
- ✓ Insufficient supply from current supplier(s);
- ✓ If it meets the specific objectives of the tender; or
- ✓ To meet unallocated demand quantities.

The quantities considered for award would be those not met under established contracts or quantities that could be reallocated from existing Arrangements after negotiation with the corresponding suppliers.

- Proposals from Bidders for both IPV and Penta/Hexavalent RFP. This tender is synchronized with RFP-DAN-2026-503939 for the supply of Pentavalent and Hexavalent vaccines due to the interdependencies between demand and supply. Some Proposers are expected to submit Bids in response to both tenders. To avoid duplication and ensure efficiency, general corporate information required under both RFPs can be submitted as part of either Proposal provided this is explicitly mentioned. Such documentation will be shared and evaluated jointly within UNICEF.
- Awards will be determined based on the following criteria:
 - Contribution to meeting the procurement objectives
 - Products meeting the technical specifications, including WHO pre-qualification
 - Timing of product availability
 - FCA price nearest international airport
 - Consideration of Proposal and possible awards under RFP-DAN-2026-503939 for Pentavalent and hexavalent vaccine considering shared production facilities
 - Proven past performance to deliver awarded quantities. For new suppliers, UNICEF reserves the right to introduce incrementally.
 - For African Vaccine Manufacturers applying for AVMA funding support, AVMA Eligibility Status.

1.2 The detailed evaluation criteria to be used to assess the Proposals are shown in the below table:

Tender Objective	Evaluation criteria
To ensure access to an affordable IPV for all countries	<ul style="list-style-type: none"> • Price FCA nearest international airport • Validity of proposal

<p>that choose to continue to use IPV standalone vaccine and support the GPEI use of IPV for outbreak response.</p>	<ul style="list-style-type: none"> • Payment terms • Price conditions offered – alternative offers providing additional benefits in terms of affordability/prices/commercial terms • Pricing compared to other offers • Factors that influence the pricing offered to UNICEF • Explanation for price increase over previous years’ pricing (if applicable) • Reciprocity in any special contracting terms • Conditions of offer and acceptance of UNICEF General Terms of Conditions • WHO Prequalification • Compliance with WHO containment requirements • Product offered • Vial size, presentation offered • Shelf life • Type of VVM • Weight and volume, cold chain requirements • Quantity offered against demand forecast • Realistic quantity offered • Ability to supply quantities above the forecast • Delivery preparation lead-time • Realistic lead time offered • Timelines for formulation, filling and releases • Possible impact of quantities offered on other vaccine products • Annual production capacities for final filled product offered • Annual production capacity for bulk • Registration in countries (planned, pending, actual, expiry, intend to maintain) • Experience in vaccine supply and delivery: <ul style="list-style-type: none"> ○ Number of years of production and delivered quantities. ○ Customer reference list (applicable to all Suppliers with less than 3 years’ experience as a UNICEF supplier supplying against long-term agreement) • Supplier past performance (existing Suppliers): <ul style="list-style-type: none"> ○ Proven capacity to supply offered and forecasted quantities ○ Reliable and firm forecasted supply ○ Accurate monthly allocation reporting ○ Flexibility for supplying unforecasted quantities (timing, quantities) ○ Timeliness of PO acknowledgment ○ Timeliness of Notification of Goods Readiness ○ Timeliness of delivery ○ Problem solving willingness and capacity • Bidders proposing a vaccine in development or yet to achieve WHO prequalification: <ul style="list-style-type: none"> ○ Dates for clinical trials yet to be completed (Phase I, II and III) ○ Dates for national licensure in country of production ○ Date of submission to WHO PQ ○ Expected date of WHO PQ
---	---

	<ul style="list-style-type: none"> ○ Expected date of first supply to UNICEF • Account management resources (organizational chart with names) and customer service capabilities including: <ul style="list-style-type: none"> ○ Accurate and reliable planning and monitoring of NRA release, efficient order processing, accurate and complete documentation, close production follow-up, timely communication) • Initiative to resolve quality problems in a satisfactory manner • Medium and long-term plans for production of the offered vaccine, including overview of business factors affecting the decision to produce the vaccine at the offered quantities. • Agreement and conditions for storing vaccines on a need basis • Warehouse capacity for finished product, maximum storage in number of doses at any time • Agreement to outbreak response conditions and timelines for a quantity requested in Proposal • Adherence to packing and shipping requirements, including temperature monitoring devices • Compliance to mandatory bar-coding requirements • Adherence to preferred bar-coding requirements (serialization, aggregation), plans to establish an interface to TRVST
Support UNICEF commitment for localisation of manufacturing provided proposals are in line with the affordability objective.	<p>Confirmation that Bidders wishing to apply for funding from the Gavi-funded AVMA instrument in connection with this RFP:</p> <ul style="list-style-type: none"> • Have obtained an in-principle eligibility statement from Gavi in respect of the Qualifying Vaccine to which this RFP relates prior to submission of the Proposal; and • Indicate in the Proposal two prices in the Answer Sheets, section A: <ul style="list-style-type: none"> ○ one price offer that includes the applicable per dose accelerator payment; and ○ one price offer without the per dose accelerator payment. <p>Bidders are required to provide relevant information in the Answer Sheets, section B. Qualitative Proposal, under Pricing.</p> <ul style="list-style-type: none"> • Price FCA nearest international airport • Validity of proposal • Payment terms • Price conditions offered – alternative offers providing additional benefits in terms of affordability/prices/commercial terms • Pricing compared to other offers • Factors that influence the pricing offered to UNICEF • Conditions of offer and acceptance of UNICEF General Terms of Conditions • Timing of WHO Prequalification • Vial size, presentation offered • Shelf life • Type of VVM
Ensure that the supplier base for the IPV standalone	<ul style="list-style-type: none"> • Medium and long-term plans for production of the offered vaccine, including overview of business factors affecting the decision to produce the vaccine at the offered quantities.

market has the manufacturers that best serve the countries that want to continue to use IPV standalone in their routine programmes in the long term (up to 10 years following bOPV withdrawal).	<ul style="list-style-type: none"> • Price FCA nearest international airport • Validity of proposal • Compliance with WHO containment requirements
Contribute to increased ESE sustainability of the vaccine market	<ul style="list-style-type: none"> • Compliance with the annual supplier sustainability reporting request, including maintaining a sustainability focal point / account management resource (organizational chart with names) • Customer service capabilities connected to environmental and social sustainability: Collaboration on sustainability, e.g. via consultations, information sharing on environmental and social sustainability topics; and (future) performance monitoring.

1.3 Minimum Order Quantity. Bidders must declare in their Proposals if there will be any minimum order quantity(ies) for the vaccine(s) detailed in the schedule to this RFP. Any such minimum order quantities will be considered as part of the evaluation process.

1.4 Clarifications Requested by UNICEF. During the evaluation of Proposals, UNICEF may, in its sole discretion, seek clarifications from any Bidder in order for UNICEF to fully understand the Bidder's Proposal and assist in the examination, evaluation and comparison of Proposals. UNICEF may seek such clarifications through written communications or may request an interview with any Bidder.

1.5 Interpretation of Errors. UNICEF may seek clarification of any errors identified by it in a Proposal. Absent satisfactory clarification, such errors will be interpreted by UNICEF in its sole discretion. In the case of errors in the extension price that are not clarified to UNICEF's satisfaction, unit price will govern.

1.6 References. UNICEF reserves the right to contact any or all references supplied by the Bidder(s) and to seek references from other sources as UNICEF deems appropriate.

2. AWARD

2.1 Objectives of this RFP. Upon evaluation of all Proposals, taking into consideration the actual market situation for each vaccine, the forecasted quantities will be awarded to Bidders in accordance with the objectives of this RFP.

2.2 Limited Award. If a Bidder has not been a Supplier to UNICEF previously, UNICEF reserves the right to introduce the Supplier incrementally during the award period and assess the performance closely.

2.3 Award Period. UNICEF reserves the right to make an award for a shorter period of time than

announced in this RFP if, in UNICEF's opinion, this would better meet the procurement objectives of this RFP or be in the best interest of UNICEF.

- 2.6 Negotiation. UNICEF reserves the right to negotiate with the Bidder(s) in support of achieving the procurement objectives of the RFP.
- 2.7 Award Notification. UNICEF will notify the Bidder(s) that has/have been awarded the LTA(s) resulting from this solicitation process. UNICEF will also notify the other Bidders of the outcome of this solicitation process.
- 2.8 Award Debrief. Bidder(s) that has/have been awarded an LTA will be invited to a formal debriefing and award initiation meeting. Bidder(s) that do not receive an award may request a formal debriefing. During a debriefing, the strengths and weaknesses of the Proposal may be discussed. Details concerning the evaluation results of other Proposals will not be divulged, except in accordance with Section 2.9 below.
- 2.9 Award Publication. UNICEF will make each award public by publishing the following information on the UNICEF website: the Supplier name, vaccine(s), duration of award, and total award value. UNICEF reserves the right to disclose the price and quantity information relating to any LTA(s) and related Purchase Orders resulting from this RFP. UNICEF may also make public the annual awarded Weighted Average Prices (WAPs) for each vaccine presentation.
- 2.10 Bidder Acknowledgement. The Bidder acknowledges and accepts the decision of UNICEF as to whether its Proposal meets the minimum requirements in this RFP and UNICEF's evaluation of the Proposal.

3. The LTA and UNICEF's GENERAL TERMS AND CONDITIONS OF CONTRACT (GOODS)

- 3.1 The terms set out in UNICEF's standard LTA for vaccines will apply to any LTA awarded in connection with this RFP and any linked Purchase Orders issued under such LTA.
- 3.2 UNICEF's General Terms and Conditions of Contract (Goods) which are attached at Annex A to this RFP will apply to any LTA and linked Purchase Orders awarded in connection with this RFP.
- 3.3 By signing the Proposal Form, each Bidder is deemed to have confirmed its acceptance of the UNICEF General Terms and Conditions (Goods). The Bidder understands that if it proposes any amendments or additional terms to the LTA or the UNICEF General Terms and Conditions (Goods), these must be clearly detailed in the Proposal and may negatively affect the evaluation of the Proposal.

4. RIGHTS OF UNICEF

- 4.1 UNICEF reserves the following rights:
 - (a) to accept any Proposal, in whole or in part; to reject any or all Proposals; or to cancel this solicitation process in its entirety and re-tender if it so chooses;
 - (b) to request additional information from the Bidder and to verify any information contained in

Bidder's response (and the Bidder will provide UNICEF with its reasonable cooperation with such verification);

(c) to invalidate any Proposal received from a Bidder that, in UNICEF's sole opinion has previously failed to perform satisfactorily or complete contracts or Purchase Orders on time, or UNICEF believes is not in a position to perform the LTA provided however that UNICEF's failure to invalidate a Proposal does not constitute an acceptance that the Proposer is in a position to perform any LTA issued as a result of this RFP or any Purchase Order issued under such LTA;

(d) to invalidate any Proposal that, in UNICEF's sole opinion, fails to meet the requirements and instructions stated in this RFP;

(e) to suspend negotiations or withdraw an award to a Bidder at any time up until an LTA has been signed with such Bidder. UNICEF is not required to provide any justification but will give notice prior to any such suspension of negotiations or withdrawal of award.

(f) to retender should the result of the tender be deemed nonresponsive by UNICEF.

4.2 UNICEF is not liable to any Bidder for any costs, expense or loss incurred or suffered by such Bidder in connection with this RFP or solicitation process, including, but not limited to, any costs, expense or loss incurred as result of UNICEF exercising any of its rights in paragraph 4.1 above.

4.3 Each Bidder will permit UNICEF, either itself or through a designated representative entity, to have access to the facilities where the products offered are manufactured, at all reasonable times during the tender period to assess the manufacturing site and processes for the production, quality control, quality assurance and packing of the products. The Bidder will provide reasonable assistance to the representatives, including copies of any documentation (including, but not limited to, test results or quality control reports) as may be necessary. Failure to do so may result in the rejection of the Proposal. The inspection may be carried out in conjunction with the appropriate national authority.

PART V – BIDDER REPRESENTATIONS

1. GENERAL REPRESENTATIONS

By submitting its Proposal in response to this RFP, the Bidder confirms to UNICEF as at the Submission Deadline and throughout the validity period of the Proposal:

- 1.1 The Bidder has (a) the full authority and power to submit the Proposal and to enter into any resulting LTA and linked Purchase Order(s), and (b) all rights, licenses, authority and resources necessary, as applicable, to develop, source, manufacture and supply the Goods and to perform its other obligations under any resulting LTA and linked Purchase Order(s). The Bidder has not and will not enter into any agreement or arrangement that restrains or restricts any person's rights to use, sell, dispose of or otherwise deal with the Goods.
- 1.2 All of the information it has provided to UNICEF concerning the Goods and the Bidder is true, correct, accurate and not misleading.
- 1.3 The Bidder is financially solvent and is able to supply the Goods to UNICEF in accordance with the requirements described in this RFP.
- 1.4 The use or supply of the Goods does not and will not infringe any patent, design, trade-name or trade-mark.
- 1.5 The development, manufacture and supply of the Goods has complied, does comply, and will comply with all applicable laws, rules and regulations.
- 1.6 The Bidder will fulfill its commitments with the fullest regard to the interests of UNICEF and will refrain from any action which may adversely affect UNICEF or the United Nations.
- 1.7 It has the personnel, experience, qualifications, facilities, financial resources and all other skills and resources to perform its obligations under any resulting LTA and linked Purchase Order(s).
- 1.8 The Bidder agrees to be bound by the decisions of UNICEF, including but not limited to, decisions as to whether the Bidder's Proposal meets the requirements and instructions stated in this RFP and the results of the evaluation process.

2. ETHICAL STANDARDS

UNICEF requires that all Bidders observe the highest standard of ethics during the entire solicitation process, as well as the duration of any LTA that may be awarded as a result of this solicitation process. UNICEF also actively promotes the adoption by its Suppliers of robust policies for the protection and safeguarding of children and the prevention and prohibiting of sexual exploitation and sexual abuse.

By submitting its Proposal in response to this RFP, the Bidder makes the following representations and warranties to UNICEF as at the Submission Deadline and throughout the validity period of the Proposal:

- 2.1 In respect of all aspects of the solicitation process the Bidder has disclosed to UNICEF any situation that may constitute an actual or potential conflict of interest or could reasonably be perceived as a conflict of interest. In particular, the Bidder has disclosed to UNICEF if it or any of its affiliates is, or has been in the past, engaged by UNICEF to provide services for the preparation of the design, specifications, cost analysis/estimation, and other documents to be used for the procurement of the Goods requested under this RFP; or if it or any of its affiliates has been involved in the preparation and/or design of the programme/project related to the Goods requested under this RFP.
- 2.2 The Bidder has not unduly obtained, or attempted to obtain, any confidential information in connection with the solicitation process and any LTA and linked Purchase Order(s) that may be awarded as a result of this solicitation process.
- 2.3 No official of UNICEF or of any United Nations System organisation has received from or on behalf of the Bidder, or will be offered by or on behalf of the Bidder, any direct or indirect benefit in connection with this RFP including the award of the LTA and linked Purchase Order(s) to the Bidder. Such direct or indirect benefit includes, but is not limited to, any gifts, favours or hospitality.
- 2.4 The following requirements with regard to former UNICEF officials have been complied with and will be complied with:
- (a) During the one (1) year period after an official has separated from UNICEF, the Bidder may not make a direct or indirect offer of employment to that former UNICEF official if that former UNICEF official was, during the three years prior to separating from UNICEF, involved in any aspect of a UNICEF procurement process in which the Bidder has participated.
 - (b) During the two (2) year period after an official has separated from UNICEF, that former official may not, directly or indirectly on behalf of the Bidder, communicate with UNICEF, or present to UNICEF, about any matters that were within such former official's responsibilities while at UNICEF.
- 2.5 Neither the Bidder nor any of its affiliates, or personnel or directors, is subject to any sanction or temporary suspension imposed by any United Nations System organisation or other international inter-governmental organisation. The Bidder will immediately disclose to UNICEF if it or any of its affiliates, or personnel or directors, becomes subject to any such sanction or temporary suspension. If the Bidder or any of its affiliates, or personnel or directors becomes subject to any such sanction or temporary suspension during the validity of the Proposal, UNICEF will be entitled to invalidate the Proposal.
- 2.6 The Bidder will (a) observe the highest standard of ethics; (b) use its best efforts to protect UNICEF against fraud, in the solicitation process and in the performance of any resulting LTA and linked Purchase Order(s); and (c) comply with the applicable provisions of UNICEF's Policy Prohibiting and Combatting Fraud and Corruption which can be accessed on the UNICEF website at <https://www.unicef.org/supply/resources/procurement-policies>. In particular, the Bidder will not engage, and will ensure that its personnel, agents and sub-contractors do not engage, in any corrupt, fraudulent, coercive, collusive or obstructive conduct as such terms are defined in UNICEF's Policy Prohibiting and Combatting Fraud and Corruption.

- 2.7 The Bidder will comply with all laws, ordinances, rules and regulations bearing upon its participation in this solicitation and the UN Supplier Code of Conduct (available at the United Nations Global Marketplace website - www.ungm.org).
- 2.8 Neither the Bidder nor any of its affiliates, is engaged, directly or indirectly, (a) in any practice inconsistent with the rights set forth in the Convention on the Rights of the Child, including Article 32, or the International Labour Organisation's Convention Concerning the Prohibition and Immediate Action for the Elimination of the Worst Forms of Child Labour, No. 182 (1999); or (b) in the manufacture, sale, distribution, or use of anti-personnel mines or components utilised in the manufacture of anti-personnel mines.
- 2.9 The Bidder has taken and will take all appropriate measures to prevent sexual exploitation or abuse of anyone by its personnel including its employees or any persons engaged by the Bidder to perform any services in the Bidder's participation in this solicitation. For these purposes, sexual activity with any person less than eighteen years of age, regardless of any laws relating to consent, will constitute the sexual exploitation and abuse of such person. The Bidder has taken and will take all appropriate measures to prohibit its personnel including its employees or other persons engaged by the Bidder, from exchanging any money, Goods, services, or other things of value, for sexual favours or activities or from engaging in any sexual activities that are exploitive or degrading to any person.
- 2.10 The Bidder confirms that it has read UNICEF's Policy on Conduct Promoting the Protection and Safeguarding of Children. The Bidder will ensure that its Personnel understand the notification requirements expected of them and will establish and maintain appropriate measures to promote compliance with such requirements. The Bidder will further cooperate with UNICEF's implementation of this Policy.
- 2.11 The Bidder will inform UNICEF as soon as it becomes aware of any incident or report that is inconsistent with the undertakings and confirmations provided in this Section 2.
- 2.12 Each of the provisions in Section 2 of this Part V constitutes an essential condition of participation in this solicitation process. In the event of a breach of any of these provisions, UNICEF is entitled to disqualify the Bidder from this solicitation process and/or any other solicitation process, and to terminate any LTA and linked Purchase Order(s) that may have been awarded as a result of this solicitation process, immediately upon notice to the Bidder, without any liability for termination charges or any liability of any kind. In addition, the Bidder may be precluded from doing business with UNICEF and any other entity of the United Nations System in the future.

3. AUDIT

- 3.1 From time to time, UNICEF may conduct audits or investigations relating to any aspect of an LTA and/or linked Purchase Order awarded in relation to this RFP, including but not limited to the award of the LTA and/or linked Purchase Order and the Bidder's compliance with the provisions of Section 2 above. The Bidder will provide its full and timely cooperation with any such audits or investigations, including (but not limited to) making its personnel and any relevant data and documentation available for the purposes of such audits or investigations, at reasonable times and on reasonable conditions, and granting UNICEF and those undertaking such audits or

investigations access to the Bidder's premises at reasonable times and on reasonable conditions in connection with making its personnel and any relevant data and documentation available. The Bidder will require its sub-contractors and its agents to provide reasonable cooperation with any audits or investigations carried out by UNICEF.

PART VI: ANSWER SHEETS

Answer Sheets / Checklist

This form serves as a checklist for preparation of your Proposal. Please complete the Answer Sheets in accordance with the instructions in the RFP document and return them as part of your proposal submission. No alteration to format of sheets shall be permitted.

As indicated in the Part II, Section 4 of the RFP document, the Proposal must include a signed PROPOSAL FORM in original. The ANSWERING SHEETS, apart from the PROPOSAL FORM, can be submitted in MS Word format, if possible.

Commercial Proposal

▪ Proposal Form	☐
▪ Proposer Information Sheet	☐
▪ Commercial Proposal Sheet (Quantitative & Qualitative)	☐
▪ Vaccine Registration Status Sheet	☐

Technical Proposal

▪ Technical Proposal Sheet	☐
▪ Packing Details Sheet	☐

COMMERCIAL PROPOSAL

PROPOSAL FORM

Important: The company identified as Proposer will be the party to which UNICEF will issue its LTA(s)/PO(s) in case of award resulting from this solicitation process.

Name of Proposer:	[INSERT NAME OF PROPOSER]]	Date:	Select date
RFP reference:	RFP-DAN-2026-503926		

Part 1: Declaration

The undersigned, being a duly authorized representative of the Company, represents and declares that:

		YES	NO
1.	The Company and its Management ³ have not been found guilty pursuant to a final judgment or a final administrative decision of any of the following:		
	a. Fraud;	☐	☐
	b. Corruption;	☐	☐
	c. Conduct related to a criminal organisation;	☐	☐
	d. Money laundering or terrorist financing;	☐	☐
	e. Terrorist offences or offences linked to terrorist activities;	☐	☐
	f. Sexual exploitation and abuse;	☐	☐
	g. Child labour, forced labour, human trafficking; or	☐	☐
	h. Irregularity (non-compliance with any legal or regulatory requirement applicable to the Company or its Management).	☐	☐
2.	The Company and its Management have not been found guilty pursuant to a final judgment or a final administrative decision of grave professional misconduct.	☐	☐
3.	The Company and its Management are not: bankrupt, subject to insolvency or winding-up procedures, subject to the administration of assets by a liquidator or a court, in an arrangement with creditors, subject to a legal suspension of business activities, or in any analogous situation arising from a similar procedure provided for under applicable national law.	☐	☐
4.	The Company and its Management have not been the subject of a final judgment or a final administrative decision finding them in breach of their obligations relating to the payment of taxes or social security contributions.	☐	☐
5.	The Company and its Management have not been the subject of a final judgment or a final administrative decision which found they created an entity in a different jurisdiction with the intent to circumvent fiscal, social or any other legal obligations in the jurisdiction of its registered office, central administration, or principal place of business (creating a shell company).	☐	☐
	The Company and its Management have not been the subject of a final judgment or a final administrative decision which found the Company was created with the intent referred to in point (5) (<i>being a shell company</i>)	☐	☐

The UNICEF reserves the right to disqualify the Company suspend or terminate any contract or other arrangement between the UNICEF and the Company, with immediate effect and without liability, in the event of any misrepresentation made by the Company in this Declaration. It is the responsibility of the Company to immediately inform the UNICEF of any changes in the situations declared. This Declaration is in addition to, and does not replace or cancel, or operate as a waiver of, any terms of contractual arrangements between the UNICEF and the Company.

Part 2: Confirmation of Proposal

The Undersigned, having read the Instructions to Proposers of this Request for Proposal and all related documents hereby offers to supply the Goods to meet the overall objectives sought in accordance with any specifications stated, under the conditions and in quantities, at prices and within the number of days as indicated in your Proposal, and subject to all Terms

³ “Management” means any person having powers of representation, decision-making or control over the Organization. This may include, for example, executive management and all other persons holding downstream managerial authority, anyone on the board of directors, and controlling shareholders

and Conditions set out or specified in this RFP-DAN-2026-503926 and accepting that any Long Term Arrangement(s) resulting from this RFP shall contain the UNICEF General Terms and Conditions and any other terms and conditions specified in this RFP.

I, the undersigned, certify that I am duly authorized by [INSERT NAME OF PROPOSER]] to sign this Proposal.

Signature: _____
Date: _____
Name: _____
Title: _____
Company as per the certificate of incorporation: _____
Postal Address: _____
Tel No.: _____
Email: _____
Validity of Offer: _____

Please indicate which of the following terms of payment are offered under this Proposal:
10 days 3.0% _____ 15 days 2.5% _____ 20 days 2.0% _____
30 days net _____ Other _____

Any requested EXCEPTIONS or CLARIFICATIONS to the requirements defined by UNICEF in this Request for Proposal and all related documents, including UNICEF’s General Terms and Conditions are to be described by the Proposer below. Additional pages may be attached. Request for EXCEPTIONS after an AWARD has been made may result in invalidation of the Proposal:

[Stamp with official stamp of the proposer]

PROPOSER INFORMATION SHEET

<p>Are you a UNGM registered vendor?</p> <p>Refer to Part II, Section 1.2 of this Request for Proposal</p>	<p>☐ Yes [insert UNGM vendor number]</p> <p>☐ No*</p> <p>*If your company has not yet registered through the UNGM, please submit an application through the UNGM website at http://www.ungm.org/Account/Registration</p> <p>Please note that while Basic level registration is sufficient for evaluation purposes, Proposers are highly encouraged to register at least at Level 1.</p>
<p>Are you a UNICEF vendor?</p>	<p>☐ Yes ☐ No</p>

COMMERCIAL PROPOSAL SHEET

A. Quantitative Proposal

Name of Proposer:	[Insert Name of Proposer]]	Date:	Select date
RFP reference:	RFP-DAN-2026-503926		

IPV 1 dose vial - Accelerated Hexavalent Transition						
Quantities per year in vials and doses: 2028: 700,000 vials (700,000 doses) 2029: 400,000 vials (400,000 doses) 2030: 400,000 vials (400,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

IPV 1 dose vial – Limited Hexavalent Transition						
Quantities per year in vials and doses: 2028: 700,000 vials (700,000 doses) 2029: 700,000 vials (700,000 doses) 2030: 700,000 vials (700,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

* Offers can be in USD only (in which case only the USD column needs to be completed). If offer is provided in EURO please ensure that both USD & EURO prices are given. Please refer to Part III, Section 6.2, CURRENCY OF PROPOSALS for further information. Offers expressed only in EURO will be invalidated.

** Please indicate in the column “conditions/discounts” with check mark if there are any conditions/discounts associated with the price offered in your Proposal. Please outline the details of the conditions/discounts below (Please refer to Part III, Section 6.8).

IPV 5 dose vial - Accelerated Hexavalent Transition						
Quantities per year in vials and doses: 2028: 8,200,000 vials (41,000,000 doses) 2029: 5,400,000 vials (27,000,000 doses) 2030: 4,000,000 vials (20,000,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

IPV 5 dose vial – Limited Hexavalent Transition						
Quantities per year in vials and doses: 2028: 11,600,000 vials (58,000,000 doses) 2029: 10,800,000 vials (54,000,000 doses) 2030: 10,200,000 vials (51,000,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

* Offers can be in USD only (in which case only the USD column needs to be completed). If offer is provided in EURO please ensure that both USD & EURO prices are given. Please refer to Part III, Section 6.2, CURRENCY OF PROPOSALS for further information. Offers expressed only in EURO will be invalidated.

** Please indicate in the column “conditions/discounts” with check mark if there are any conditions/discounts associated with the price offered in your Proposal. Please outline the details of the conditions/discounts below (Please refer to Part III, Section 6.8).

IPV 10 dose vial - Accelerated Hexavalent Transition						
Quantities per year in vials and doses: 2028: 3,700,000 vials (37,000,000 doses) 2029: 2,100,000 vials (21,000,000 doses) 2030: 2,100,000 vials (21,000,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

IPV 10 dose vial – Limited Hexavalent Transition						
Quantities per year in vials and doses: 2028: 3,700,000 vials (37,000,000 doses) 2029: 2,100,000 vials (21,000,000 doses) 2030: 2,100,000 vials (21,000,000 doses)						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

* Offers can be in USD only (in which case only the USD column needs to be completed). If offer is provided in EURO please ensure that both USD & EURO prices are given. Please refer to Part III, Section 6.2, CURRENCY OF PROPOSALS for further information. Offers expressed only in EURO will be invalidated.

** Please indicate in the column “conditions/discounts” with check mark if there are any conditions/discounts associated with the price offered in your Proposal. Please outline the details of the conditions/discounts below (Please refer to Part III, Section 6.8).

ALTERNATIVE PROPOSAL						
Vaccine: Description: Vial size: Quantities per year in vials and doses:						
Period	Quantity offered (doses)	Quantity offered (vials)	Price in USD*/vial, FCA [Insert nearest International Airport]]	Price in EUR*/vial FCA [Insert nearest International Airport]]	Conditions/ Discounts**	Total Amount (USD)
2028						
2029						
2030						

* Offers can be in USD only (in which case only the USD column needs to be completed). If offer is provided in EURO please ensure that both USD & EURO prices are given. Please refer to Part III, Section 6.2, CURRENCY OF PROPOSALS for further information. Offers expressed only in EURO will be invalidated.

** Please indicate in the column “conditions/discounts” with check mark if there are any conditions/discounts associated with the price offered in your Proposal. Please outline the details of the conditions/discounts below (Please refer to Part III, Section 6.8).

B. Qualitative Proposal

Experience and past performance. Account management.	
1	Demonstrate proven experience and qualification in development, supply and delivery of vaccines and/or biologicals, including the offered product(s). Advise number of years of experience in production and delivery of the offered product. <i>(Part III, Section 1)</i> <u>Proposers' response:</u>
2	For Proposers with less than 3 years of experience as a vaccine supplier to UNICEF, please provide a full customer reference list, delivery report and delivery performance report for the minimum period of the past 3 years. Advise of the reasons for delays in deliveries and frequency, as well as measures taken to resolve the delays. Please also advise the total annual quantities supplied to other customers. <i>(Part III, Section 1)</i> Proposers should be prepared to substantiate the claimed experience by presenting copies of relevant documents and references if so requested by UNICEF. <u>Proposers' response:</u>
3	Provide organizational charts and names of the responsible persons within each following department: Production, Quality Assurance, Governmental Affairs, Shipping/Logistics, Sales and Marketing, Environmental Social and Governance (ESG), Barcoding/Serialization, specifying the name(s) of the person(s) who will be the primary contact for UNICEF. <i>(Part III, Section 3)</i> <u>Proposers' response:</u>
Pricing	
4	Given that UNICEF has requested prices that are affordable to the poorest country governments and donors please indicate factors influencing your price setting. Please also provide explanation of any price increase over previous years' pricing (if applicable). <i>(Part III, Section 6)</i> . <u>Proposers' response:</u>
5	Bidders who want to apply for funding from the Gavi-funded African Vaccine Manufacturing Accelerator (AVMA) instrument in connection with this tender must confirm the following: Bidder is eligible and has obtained an "in-principle eligibility statement" from Gavi for the Qualifying Vaccine related to this tender and it is attached to this proposal. <u>Proposers' response:</u> Information in the original application form remains the same. If not, Bidder should provide details of any changes for re-assessment of eligibility. <u>Proposers' response:</u> Confirm that the Proposal includes pricing with the accelerator payment that may eventually be applicable. <u>Proposers' response:</u>
Volumes offered, timelines	
6	Proposed Quantity: Explain the key determinants for the proposed quantity to be available during the proposed timeframe, as well as any key risks. <u>Proposers' response:</u>
7	Delivery preparation lead time (administration of UNICEF's Purchase Order, packing, markings etc.) for any order within above mentioned schedule, in number of days <i>(Part III, Section 7)</i> : <u>Proposers' response:</u>
8	In case IPV is needed for an outbreak response please indicate the shortest delivery preparation lead time <u>Proposers' response:</u>

9	<p>Please include in your proposal timelines for bulk production (from start of the production process until bulk is ready for formulation and filling) and timelines for formulation, filling, labelling, and having the product released both internally and by the relevant NRA.</p> <p>Bulk production: Formulation: Filling: Labelling and Internal release process: NRA release:</p>
10	<p>Please provide information on your medium and long-term plans for production of the vaccine(s) being offered, or of vaccines that may be offered in the future, including overview of business factors affecting the decision to produce the vaccine at the quantities offered to UNICEF. <i>(Part III, Section 2)</i></p> <p><u>Proposers' response:</u></p>
11	<p>Please advise whether the production of any of the vaccines offered affects the production, or potential production, of another vaccine being offered or supplied by your company. If yes, please advise which vaccines. In addition, please indicate whether facilities for bulk production and fill and finish are dedicated, multipurpose and/or shared facilities.</p> <p><u>Proposers' response:</u></p>
12	<p>Please advise if the company will be able to supply quantities above the forecast and indicate the lead times for each product offered as part of your Proposal, for quantities above forecast.</p>
Other	
13	<p>Storage of vaccines shall be under controlled environmental conditions to facilitate the conservation of the vaccines. Vaccines will be kept at the manufacturers' premises until these are either supplied through UNICEF Purchase Order(s) or reach expiry date. Please confirm that your company will bear the responsibility and cost of destruction should the vaccines, by any event, reach expiry date when stored at your warehouse.</p> <p><u>Proposers' response:</u></p>
14	<p>Please provide your company's ESG policy (or equivalent) and confirm contact persons and their e-mail addresses with whom UNICEF can engage on questions connected to progress on environmental and social sustainability implementation operations.</p> <p><u>Proposers' response:</u></p>
15	<p>Please provide your company's plans and status on establishment of digital interface to TRVST, if not already established. Please confirm contact persons and their e-mail addresses with whom UNICEF can engage on questions connected to progress on onboarding to TRVST.</p> <p><u>Proposers' response:</u></p>
16	<p>Please advise what is your company's maximum annual capacity for IPV bulk production and finished product.</p> <p><u>Proposers' response:</u></p>
17	<p>Please confirm if your Polio Essential Facility has a certificate of containment (CC) or an interim certificate of containment (ICC). If you have an ICC please include your plans and timelines to achieve the CC.</p> <p><u>Proposers' response:</u></p>
18	<p>Bidders not producing the vaccine offered or their own vaccine bulk concentrate must indicate the source(s) for the vaccine quantity offered. Bidders will provide evidence of the contractual agreements for the quantities being offered. Furthermore, the Bidder must confirm that the quantities offered do not violate</p>

	any contractual commitments made between the Bidder and the vaccine or bulk concentrate manufacturer.
--	---

	<u>Proposers' response:</u>
--	-----------------------------

QUARTERLY OFFERED QUANTITIES (DOSES)
Year 2028 to 2030

Vaccine (quantity in doses)	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	Annual Total
2028					
2029					
2030					

For Proposers offering more than one product presentation please provide separate quarterly offered sheets for each presentation.

VACCINE REGISTRATION STATUS SHEET

Please list the completed registrations for each vaccine and each presentation included in the Proposal. Rows may be added to the table as necessary. *(Part III, Section 1)*

Product	Presentation	Country	NRA name	Date of registration	Date of expiry	Registration reference	Intention to renew	For use in private market or national program

Please provide any additional information on planned and pending registrations. *(Part III, Section 2):*

TECHNICAL PROPOSAL SHEET

Proposers are requested to submit one technical proposal form for each vaccine product/presentation offered:

Name of Proposer:	[Insert Name of Proposer]]	Date:	Select date
RFP reference:	RFP-DAN-2026-503926		
Vaccine description			
Qty offered, in doses and vials:	2028: doses/vials 2029: doses/vials 2030: doses/vials		
WHO pre-qualified product	☐ Yes ☐ No* *If no, please include information requested as per Section IV, 1.1: Proposals of Vaccines not yet WHO Pre-Qualified.		
Language on label/package insert	Label: Package insert:		
Samples	☐ Yes If samples provided are different from those submitted to WHO for pre-qualification, the differences should be explained: ☐ No Please provide justification as per Section 3.5 of Part II:		
Vaccine Vials Monitor (VVM)	☐ Yes ☐ No If yes, which type: If no, please indicate feasibility to include VVM in the future, including timeline:		

Barcodes	<p>A GS1- barcode with GTIN, Expiry Date and Batch number on secondary pack and higher levels is a mandatory requirement. Please indicate your barcode implementation:</p> <p>At secondary packing level, in accordance with Annex C: ☐ Yes ☐ No</p> <p>At tertiary packing level, in accordance with Annex C: ☐ Yes ☐ No</p> <p>Please advise the type of barcode which is included (i.e. GS1-128 barcode, 2D Data Matrix barcode) and at which level of packing:</p> <p>Please confirm implementation of expiry date on secondary pack as MM. YYYY, MMM.YYYY or MMM.YY and reflected in barcode encoded data with the last day of respective month, in accordance with Annex C: ☐ Yes ☐ No</p> <p>Where the diluent is packed separately, please provide information on bar code inclusion on secondary and tertiary packing level for diluent:</p> <p>☐ Yes ☐ No ☐ Not relevant (no diluent supplied in separate secondary pack)</p>
Barcodes serialization and aggregation	<p>Serialisation and aggregation of barcodes is a preferred requirement. Please advise if serialisation and aggregation is already implemented for the offered product and if not, whether you are working towards implementation thereof, including the timeline for implementation.</p> <p>Serialization at secondary packing level, in accordance with Annex C: ☐ Yes ☐ No*</p> <p>Serialization at tertiary packing level, in accordance with Annex C: ☐ Yes ☐ No*</p> <p>Aggregation in place, in accordance with Annex C: ☐ Yes ☐ No*</p> <p>Where the diluent is packed separately, please provide information on serialized bar code inclusion on secondary and tertiary packing level for diluents: ☐ Yes ☐ No* ☐ Not relevant (no diluent supplied in separate secondary pack)</p> <p>Please advise type of barcode which is included (i.e. 2D Data Matrix barcode, GS1-128 barcode) and at which level of packing:</p> <p>Please confirm implementation of expiry date on secondary pack as MM. YYYY, MMM.YYYY or MMM.YY and reflected in barcode encoded data with the last day of respective month, in accordance with Annex C: ☐ Yes ☐ No</p> <p>*Indicate whether you are working towards such implementation and provide timeline for implementation:</p>
Data upload to TRVST / TRVST onboarding	<p>Upload of barcode encoded data to TRVST is a preferred requirement and would require onboarding to TRVST to make data available for subsequent use cases.</p> <p>For those Suppliers that have an established interface to TRVST, including automatic data upload for the respective GTIN(s) (GTIN/vaccine product(s) offered via this tender), tick the following box: ☐ <i>TRVST interface fully operational for offered product</i> and skip the remainder of this TRVST onboarding section.</p> <p>For Suppliers that have not yet established or initiated the interface connection to TRVST (in accordance with Annex C), please indicate whether you are working towards such implementation and provide timeline for implementation for the offered product:</p>

Continuous quality assurance	In the past, how has your company been able to maintain the quality level for the supplied products? If your company has faced quality problems, please provide frequency and explanations as well as measures taken for improvement.
Total annual production capacity	<p>Bulk:</p> <p>Final filled product for the offered vaccine:</p> <p>Source of bulk:</p> <p>Source of fill and finish:</p> <p>If you are not bulk producer, or you do not perform the fill and finish for the product offered, please include evidence of contractual access to bulk/fill and finish capacity.</p>
Batch size	<p>[Please provide minimum and maximum batch size for bulk production:</p> <p>Please provide minimum and maximum batch size (throughput) for fill and finish:]</p>
Storage capacity	<p>Please indicate cold storage capacity for bulk and finished product, indicating the maximum storage capacity in number of doses at any time.</p> <p>Bulk:</p> <p>Finished product:</p>
Capacity Expansion	<p>In case of plans to scale-up production, please provide information on:</p> <ol style="list-style-type: none"> Milestones and timelines related to any scale up in production capacity, including if required, any new facilities Milestones and timelines for anticipated approval by the NRA Timelines for WHO approval as applicable Expected timeline for release and availability to UNICEF of first product from new capacity <p><u>Proposers' response:</u></p>
Shelf life	<p>Remaining minimum shelf life at the time of shipment:</p> <p>Total shelf life of the vaccine offered:</p> <p>Please provide information on any plans to increase the current total shelf life of the vaccine including the timelines related to anticipated approval by the NRA and WHO, as applicable.</p>
Vaccination schedule:	<u>Proposers' response:</u>
Country of Origin:	<u>Proposers' response:</u>
National Regulatory Authority (NRA) of record:	<u>Proposers' response:</u>

<p>Variations/changes to licensure and WHO prequalification dossier</p>	<p>Are there any variations currently pending for review and approval by:</p>
	<p>NRA of record ☐ Yes ☐ No</p>
	<p>WHO PQT ☐ Yes ☐ No</p>
	<p>If you answered “yes” to any of the above, please provide information on the nature of the variation, what is the anticipated timeline for endorsement and whether the variation will require updates for licensure by NRAs in other countries.</p>
<p><u>Proposers’ response:</u></p>	

PACKING DETAILS SHEET

Proposers are requested to provide UNICEF with packing details for each vaccine product offered using this form:

Vaccine description																							
Description of insulated shipper/shipping container and transport temperature specification																							
Type of coolant	☐ Ice packs ☐ Dry Ice* *If the vaccine is packed using dry ice, please advise of any plans to change to packing with ice packs. Also, please advise of any effect this would have on quantity, weight and dimension.																						
Type of temperature monitoring device and recording period																							
PACKING																							
<table border="1"> <thead> <tr> <th>Standard EXPORT Packing Dimensions and Weight</th> <th>Vaccine</th> <th>Diluent</th> </tr> </thead> <tbody> <tr> <td>Total no. of Doses per EXPORT Packing</td> <td></td> <td></td> </tr> <tr> <td>Total no. of Vials per EXPORT Packing</td> <td></td> <td></td> </tr> <tr> <td>Dimensions: Length Width Height</td> <td></td> <td></td> </tr> <tr> <td>Gross Weight</td> <td></td> <td></td> </tr> <tr> <td>Net Weight</td> <td></td> <td></td> </tr> <tr> <td>Number of inner cartons per EXPORT Packing</td> <td></td> <td></td> </tr> </tbody> </table>			Standard EXPORT Packing Dimensions and Weight	Vaccine	Diluent	Total no. of Doses per EXPORT Packing			Total no. of Vials per EXPORT Packing			Dimensions: Length Width Height			Gross Weight			Net Weight			Number of inner cartons per EXPORT Packing		
Standard EXPORT Packing Dimensions and Weight	Vaccine	Diluent																					
Total no. of Doses per EXPORT Packing																							
Total no. of Vials per EXPORT Packing																							
Dimensions: Length Width Height																							
Gross Weight																							
Net Weight																							
Number of inner cartons per EXPORT Packing																							
<table border="1"> <thead> <tr> <th>Standard INNER CARTON Packing Dimensions and Weight</th> <th>Vaccine</th> <th>Diluent</th> </tr> </thead> <tbody> <tr> <td>Total no. of Doses per INNER carton</td> <td></td> <td></td> </tr> <tr> <td>Total no. of Vials per INNER carton</td> <td></td> <td></td> </tr> <tr> <td>Dimensions: Length Width Height</td> <td></td> <td></td> </tr> <tr> <td>Gross Weight</td> <td></td> <td></td> </tr> <tr> <td>Net Weight</td> <td></td> <td></td> </tr> </tbody> </table>			Standard INNER CARTON Packing Dimensions and Weight	Vaccine	Diluent	Total no. of Doses per INNER carton			Total no. of Vials per INNER carton			Dimensions: Length Width Height			Gross Weight			Net Weight					
Standard INNER CARTON Packing Dimensions and Weight	Vaccine	Diluent																					
Total no. of Doses per INNER carton																							
Total no. of Vials per INNER carton																							
Dimensions: Length Width Height																							
Gross Weight																							
Net Weight																							